x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:11:19

Alloy Therapeutics announced a deal with Biogen today...

BiotechTV - News ·

2026/04/08

He discusses the Biogen deal, and how it is a sign of increased activity Alloy sees in their genetic medicines business. Plus, monoclonals vs multispecifics, and the state of discovery work today.

en-us

00:22:44

The new CEO of Stoke Therapeutics, Ian Smith,...

BiotechTV - News ·

2026/04/08

He describes how Stoke aims to up-regulate healthy genes in cases where diseases are caused by autosomal dominant haploinsufficiencies, like Dravet. He discusses the phase 1/2 data, a phase 3 that is scheduled to read out in 2027, and the regulatory history of the program.

en-us

00:13:09

Iambic's CEO Tom Miller discusses the company's...

BiotechTV - News ·

2026/04/07

He describes the multiple variables that factor in to designing new medicines with AI, how Iambic's platform has allowed it to shorten the time to get a medicine into the clinic versus traditional discovery work, and how he thinks AI will augment the work of human scientists.

en-us

00:12:56

Already this year Chai Discovery has raised a $130M...

BiotechTV - News ·

2026/04/06

He explains how Chai-2 works, and how it compares to other antibody building / binding AI models.

en-us

00:09:02

CellCentric has kicked off dosing of its first...

BiotechTV - News ·

2026/03/31

The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.

en-us

00:22:13

Solid Biosciences CEO Bo Cumo discusses recent DMD...

BiotechTV - News ·

2026/03/25

He describes data presented at the Muscular Dystophy Association Annual Meeting which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key ffor the company.

en-us

00:06:57

Christian Tidona's BioMed X and Michal Preminger are...

BiotechTV - News ·

2026/03/25

Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.

en-us

00:10:23

Apogee Therapeutics' CEO Michael Henderson discusses...

BiotechTV - News ·

2026/03/23

He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.

en-us

00:39:47

Biotech CEOs discuss the importance of culture,...

BiotechTV - News ·

2026/03/20

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive.

en-us

00:09:49

From London: Yellowstone Biosciences is leveraging an...

BiotechTV - News ·

2026/03/20

From Syncona's Capital Markets Day, CEO Jim MacDonald describes the learnings Yellowstone has gained from looking at cured AML patients from the Oxford biobank and how it is translating that into new medicines.

en-us

00:10:35

From London: Edward Hodgkin is the Executive Chair of...

BiotechTV - News ·

2026/03/20

From Syncona's Capital Markets Day, he describes Slingshot and how he believes it differs from other early stage VC investors. Once an asset is ready for the clinic, Slingshot will either partner it or build its own company.

en-us

00:11:21

From London: Purespring Therapeutics is developing a...

BiotechTV - News ·

2026/03/20

From Syncona's Capital Markets Day, CEO Haseeb Ahmed describes the science behind the platform, and make the case why IgAN, a condition that has seen a bevy of new therapies in development, is the right indication for a gene therapy.

en-us

00:14:35

From London: Resolution Therapeutics is in the clinic...

BiotechTV - News ·

2026/03/19

CEO Amir Hefni describes the ability of macrophages to reduce inflammation and reverse fibrosis in conditions like liver disease. An interim analysis for the clinical trial will read later this year.

en-us

00:11:34

From London: With science from the Francis Crick...

BiotechTV - News ·

2026/03/19

From Syncona's Capital Markets Day, ALTx founder and Francis Crick researcher Simon Boulton describes ALTs and the science behind how the company plans to target them.

en-us

00:11:54

From London: iOnctura is developing its allosteric...

BiotechTV - News ·

2026/03/19

From Syncona's Capital Markets Day, Founder and CEO Catherine Pickering walks us through the science of roginolisib and describes the current landscape for uveal melanoma. She discusses her phase 2, which is approaching a key readout.

en-us

00:13:33

From London: Spur Therapeutics is an a phase 3 for...

BiotechTV - News ·

2026/03/19

CEO Michael Parini describes the science behind how Spur's gene therapies have two key differences compared to others, including a proprietary capsid. He discusses phase 1/2 data that has already been announced, and how he thinks about the phase 3.

en-us

00:08:22

From London: Beacon Therapeutics has a phase 3 trial...

BiotechTV - News ·

2026/03/19

From Syncona's Capital Markets Day, CEO Lance Baldo describes the trial's design and the degree to which Beacon will be trying to restore vision for these patients.

en-us

00:17:52

From London: Syncona CEO Chris Hollowood discusses...

BiotechTV - News ·

2026/03/19

He talks about Syncona's listed fund, and clarifies the details of a return of capital strategy for some shareholders, and he describes the strategy of the firm's new private fund. Plus, how Syncona thinks about opportunities in life sciences today.

en-us

00:18:03

Checking in with Menlo Ventures' Partner Greg Yap to...

BiotechTV - News ·

2026/03/18

He his take on topics such as how the Baby KJ news is allowing investors and companies to think about scaling bespoke therapies, how AI might start to impact the clinical trial side of our business, and why he sees pharma adoption of AI as being important.

en-us

00:21:57

Earli, which raised $105M in two rounds, is...

BiotechTV - News ·

2026/03/17

Co-Founder & CEO Cyriac Roeding and Co-Founder & CSO David Suhy describe the science behind this approach and explain how AI is helping they move closer to the clinic. The first IND filing is scheduled to be late '26 or early '27.

en-us

413 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter